Proethos Fond vs Swedbank Robur Healthcare

Proethos Fond vs Swedbank Robur Healthcare

1. Proethos Fond

  • Security

    Proethos Fond

  • Fee

    0.65%

  • ISIN

    SE0010547778

  • Holdings

    9

2. Swedbank Robur Healthcare

  • Security

    Swedbank Robur Healthcare A

  • Fee

    1.30%

  • ISIN

    SE0000639445

  • Holdings

    25

Fund Holdings

We have information about 10 holdings in Proethos Fond, where the largest holding is Storebrand Grön Obligation A SEK (8.78), followed by Vestas (6.18) and Shimano (5.4). In comparison with Swedbank Robur Healthcare, we have 28 holdings where UnitedHealth is the largest holding (8.49), followed by Eli Lilly (8.12) and AstraZeneca (6.21).

All Holdings

Here we compare the holdings in Proethos Fond and Swedbank Robur Healthcare.

Proethos Fond Swedbank Robur Healthcare
1. Storebrand Grön Obligation A SEK
Sweden
8.78 %
1. UnitedHealth Group Inc
USA
8.49 %
2. Vestas Wind Systems A/S
Denmark
6.18 %
2. Eli Lilly and Co
USA
8.12 %
3. Shimano ADR
Japan
5.4 %
3. AstraZeneca
Sweden UK
6.21 %
4. First Solar Inc
USA
5.08 %
4. Novo Nordisk B
Denmark
5.78 %
5. Nordex SE
Germany
4.8 %
5. AbbVie Inc
USA
5.01 %
6. Ormat Technologies Inc
USA
4.33 %
6. Merck & Co Inc
Germany
4.71 %
7. NIBE Industrier B
Sweden
4.32 %
7. Thermo Fisher Scientific Inc
4.45 %
8. Central Japan Railway Co
Japan
4 %
8. McKesson Corp
USA
4.27 %
9. Enphase Energy Inc
USA
1.51 %
9. Abbott Laboratories
USA
4.24 %
- 10. Danaher Corp
USA
4.03 %
- 11. Roche Holding AG
Switzerland
3.84 %
- 12. Boston Scientific Corp
3.73 %
- 13. Centene Corp
3.56 %
- 14. Vertex Pharmaceuticals Inc
3.28 %
- 15. Sanofi SA
France
2.96 %
- 16. HCA Healthcare Inc
2.76 %
- 17. Merck KGaA
Germany
2.19 %
- 18. Cooper Companies Inc
1.78 %
- 19. Edwards Lifesciences Corp
1.62 %
- 20. Takeda Pharmaceutical Co Ltd
Japan
1.55 %
- 21. Hologic Inc
1.43 %
- 22. IQVIA Inc
1.36 %
- 23. Royalty Pharma Plc
1.36 %
- 24. Halozyme Therapeutics Inc
0.91 %
- 25. ConvaTec Group Plc
0.83 %

The list of fund holdings was last updated on July 25, 2025.